-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Results from cohort B of the VARGADO study were recently published in Clinical Oncology, focusing on Nintedanib + docetaxel after progression on first-line chemotherapy and second-line immunotherapy in patients with locally advanced, metastatic, or locally recurrent lung adenocarcinoma efficacy of third-line therapy
.
.
Between March 15, 2015, and August 2, 2021, 547 patients were enrolled in the VARGADO study
.
Between March 15, 2015, and August 2, 2021, 547 patients were enrolled in the VARGADO study
In addition, 63 (79%) patients underwent tumor mutation analysis, of which 60/63 (95%) patients had no EGFR mutation, and the EGFR mutation status of 2 patients was not reported
Among 64 evaluable patients, the objective response rate was 50% (n=32; 1 complete response, 31 partial responses), and the disease control rate was 86% (n=55)
.
Among 64 evaluable patients, the objective response rate was 50% (n=32; 1 complete response, 31 partial responses), and the disease control rate was 86% (n=55)
The median follow-up time was 12.
4 months
The median follow-up time was 12.
Notably, from second-line therapy, the median overall survival was 18.
6 months (95% CI 14.
Notably, from second-line therapy, the median overall survival was 18.
Median PFS after the start of third-line therapy was 5.
No new safety signals or unexpected toxicity
.
No new safety signals or unexpected toxicity
.
Drug-related adverse events occurred in 74% (n=59) of all treated patients, the most common being (nintedanib/docetaxel-related) diarrhea (34%/24%), decreased white blood cell count (11 %/19%) and nausea (13%/16%)
.
In conclusion, the study shows that Nintedanib + docetaxel can be an effective third-line treatment option after the progression of second-line immunotherapy for advanced lung adenocarcinoma
.
.
Studies have shown that Nintedanib + docetaxel can be an effective third-line treatment option after progression on second-line immunotherapy for advanced lung adenocarcinoma
.
Studies have shown that Nintedanib + docetaxel can be an effective third-line treatment option after progression on second-line immunotherapy for advanced lung adenocarcinoma
.
Original source:
Original source:Grohé C, Blau W, Gleiber W, Haas S, Hammerschmidt S, Krüger S, Müller-Huesmann H, Schulze M, Wehler T, Atz J, Kaiser R.
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Clin Oncol (R Coll Radiol).
2022 Jan 7:S0936-6555(21)00491-X.
doi: 10.
1016/j.
clon.
2021.
12.
010.
Epub ahead of print.
PMID: 35012901.
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Clin Oncol (R Coll Radiol).
2022 Jan 7:S0936-6555(21)00491-X.
doi: 10.
1016/j.
clon.
2021.
12.
010.
Epub ahead of print.
PMID: 35012901.
Leave a message here
